Corona Remedies IPO – Complete Details
Opening: Dec 8 – 10, 2025 | Listing: Dec 15, 2025 (BSE/NSE)
| Category | Details |
|---|---|
| Company Overview | Founded in 2004; leading player in women’s health, cardiology, pain relief & urology. 67 brands, 2,598 medical reps across 22 states, 2 plants in Gujarat, 88 R&D staff. Promoters: Dr. Kirtikumar Mehta family. Ranked 2nd largest in Indian Pharma Market (IPM) among peers. |
| IPO Dates | Open: Dec 8, 2025 Close: Dec 10, 2025 (5 PM) Allotment: Dec 11, 2025 Listing: Dec 15, 2025 (BSE/NSE) Refunds/Credit: Dec 12, 2025 |
| Price Band & Lot Size | ₹1008 – ₹1062 per share • Retail Min: 14 shares (₹14,868) • Retail Max: 182 shares (₹1,93,284) • sHNI Min/Max: 196–938 shares (₹2.08L–₹9.96L) • bHNI Min: 952 shares (₹10.11L+) |
| Issue Size | ₹655.37 Crore (Fresh Issue + OFS of 61,71,101 shares) |
| Financials (₹ Cr) |
Year → 2023 | 2024 | 2025 | Jun-25 Revenue → 891 | 1,021 | 1,202 | 349 PAT → 85 | 91 | 149 | 46 Assets → 595 | 831 | 930 | 1,012 Revenue ↑18% YoY | PAT ↑65% YoY |
| Valuation (FY25) | ROE: 27.5% | ROCE: 41.3% | EBITDA Margin: 20.6% | PAT Margin: 12.5% EPS: ₹24.43 | RoNW: 24.7% | NAV: ₹99.14 |
| Subscription & GMP | Subscription: Not started GMP: To be updated (live tracker coming soon) |
| Reservation | QIB: 50% | NII: 15% | Retail: 35% |
| Anchor Investors | Bidding: Dec 5, 2025 Lock-in: 30/90 days |
| Expert Review | Strong long-term bet – explosive PAT growth, debt-free, market leader in niche therapies. Peers (Abbott, Alkem) trade at ~45x PE. Apply for listing gains + fundamentals. |
| Registrar & Managers | Registrar: Bigshare Services Lead Managers: JM Financial, IIFL Capital, Kotak Mahindra |
| Promoter Holding | Pre-IPO: 72.50% (6.12 Cr shares) Post-IPO: To be updated |
Source: DRHP Draft
GMP & subscription status will be updated live when bidding opens
Source : DRHP Draft
Note: . If subscription levels appear low, investors are advised to apply carefully and at their own risk.
